Research Analysts Set Expectations for UTHR FY2024 Earnings

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for United Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of $25.09 per share for the year, down from their prior forecast of $25.94. The consensus estimate for United Therapeutics' current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q1 2025 earnings at $6.95 EPS, Q2 2025 earnings at $7.31 EPS, Q3 2025 earnings at $7.81 EPS, FY2025 earnings at $29.77 EPS, FY2026 earnings at $31.02 EPS, FY2027 earnings at $30.53 EPS and FY2028 earnings at $32.83 EPS.

Other equities research analysts also recently issued research reports about the company. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. The Goldman Sachs Group lifted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a report on Friday, November 1st. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a report on Monday, October 21st. Argus lifted their target price on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH lifted their target price on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $382.08.

United Therapeutics Stock Up 0.0 %

Shares of NASDAQ:UTHR traded up $0.14 during midday trading on Wednesday, reaching $370.58. The company's stock had a trading volume of 209,344 shares, compared to its average volume of 312,203. The firm has a market cap of $16.55 billion, a price-to-earnings ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics has a 1 year low of $211.61 and a 1 year high of $417.82. The business has a 50 day moving average price of $361.93 and a 200 day moving average price of $358.65.

Insider Activity

In other news, EVP Paul A. Mahon sold 7,700 shares of the business's stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 121,864 shares of company stock valued at $44,516,965. 11.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics in the fourth quarter worth approximately $25,000. Brooklyn Investment Group acquired a new stake in United Therapeutics in the third quarter worth approximately $33,000. Millstone Evans Group LLC acquired a new stake in United Therapeutics in the fourth quarter worth approximately $67,000. Capital Performance Advisors LLP acquired a new stake in United Therapeutics in the third quarter worth approximately $82,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.